Related references
Note: Only part of the references are listed.ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update
Sofia Ramiro et al.
ANNALS OF THE RHEUMATIC DISEASES (2023)
WHAT DOES IT MEAN - A GOOD RESPONSE TO NSAIDS? A SYSTEMATIC COMPARISON OF PATIENTS WITH AXIAL SPONDYLOARTHRITIS AND CONTROLS WITH CHRONIC BACK PAIN
X. Baraliakos et al.
ANNALS OF THE RHEUMATIC DISEASES (2022)
Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial
Atul Deodhar et al.
LANCET (2022)
Impact of baseline C-reactive protein levels on the response to secukinumab in ankylosing spondylitis: 3-year pooled data from two phase III studies
Juergen Braun et al.
RMD OPEN (2018)
TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss Clinical Quality Management cohort
Christoph Molnar et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force
Josef S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
Efficiency of treatment with non-steroidal anti-inflammatory drugs according to current recommendations in patients with radiographic and non-radiographic axial spondyloarthritis
Xenofon Baraliakos et al.
RHEUMATOLOGY (2017)
2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis
Desiree van der Heijde et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Effect of continuous versus on-demand treatment of ankylosing spondylitis with diclofenac over 2 years on radiographic progression of the spine: results from a randomised multicentre trial (ENRADAS)
Joachim Sieper et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Long-term effects of secukinumab on MRI findings in relation to clinical efficacy in subjects with active ankylosing spondylitis: an observational study
Xenofon Baraliakos et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Non-steroidal anti-inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis)
Feline P. B. Kroon et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2015)
Maintenance of biologic-free remission with naproxen or no treatment in patients with early, active axial spondyloarthritis: results from a 6-month, randomised, open-label follow-up study, INFAST Part 2
J. Sieper et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1
J. Sieper et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort
Sofia Ramiro et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1)
Joachim Sieper et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort
Denis Poddubnyy et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
The appropriate use of non-steroidal anti-inflammatory drugs in rheumatic disease: opinions of a multidisciplinary European expert panel
Gerd Burmester et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
MRI and clinical findings in patients with ankylosing spondylitis eligible for anti-tumour necrosis factor therapy after a short course of etoricoxib
S. J. Jarrett et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection
M. Rudwaleit et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, double-blind, controlled study
J. Sieper et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab -: Results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study
J Braun et al.
ARTHRITIS AND RHEUMATISM (2006)
Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis -: A randomized clinical trial
A Wanders et al.
ARTHRITIS AND RHEUMATISM (2005)
International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis
J Braun et al.
ANNALS OF THE RHEUMATIC DISEASES (2003)
Treatment of active ankylosing spondylitis with infliximab:: a randomised controlled multicentre trial
J Braun et al.
LANCET (2002)
Share Paper
